ロード中...
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma
BACKGROUND: We conducted a phase I trial of cisplatin-pemetrexed-imatinib mesylate, an oral PDGFR inhibitor, in chemo-naive MPM patients. METHODS: A standard 3+3 dose-escalating trial was used with the endpoints of MTD, response rate, survival, safety/toxicity and tumor PDGFR levels. RESULTS: 17 MPM...
保存先:
| 出版年: | Clin Lung Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080907/ https://ncbi.nlm.nih.gov/pubmed/24492162 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.008 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|